Modulated release from biocompatible polymers

Details Modulated release from biocompatible polymers Modulated release from biocompatible polymers

1999-03-23

2002-04-09

Spear, James M. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Matrices

C424S484000, C424S487000, C424S489000, C424S425000, C424S426000, C514S772300, C514S772600, C514S805000, C514S965000

Reexamination Certificate

active

06368630

ABSTRACT:

BACKGROUND OF THE INVENTION
Many illnesses or conditions require a constant level of medicaments or agents in vivo to provide the most effective prophylactic, therapeutic or diagnostic results. In the past, medicaments were given in doses at intervals which resulted in fluctuating medication levels.
Attempts to control and steady medication levels have more recently included the use of many biodegradable substances, such as poly(lactide) or poly(lactide-co-glycolide microspheres containing the medicament. The use of these microspheres provided an improvement in the controlled release of medicaments by utilizing the inherent biodegradability of the polymer to improve the release of the medicament and provide a more even, controlled level of medication. However, in some cases, biodegradable polymers under in vivo conditions can have an initial level of medicament release, which is too high or too low, and after a period of hydration can substantially degrade to thereby limit the effective life of the controlled release microspheres. Therefore, a need exists for a means of modulating the controlled release of medicament from a biodegradable polymer to provide a higher level of initial medicament release and to provide longer periods of fairly consistent medicament release levels in vivo.
SUMMARY OF THE INVENTION
The present invention relates to a composition for the modulated release of a biologically active agent. The composition comprises a biocompatible polymeric matrix, a biologically active agent which is dispersed within the polymeric matrix, and a metal cation component which is separately dispersed within the polymeric matrix, whereby the metal cation component modulates the release of the biologically active agent from the polymeric matrix.
The present invention also relates to a method for modulating the release of a biologically active agent from a polymeric matrix, comprising the steps of dissolving a biocompatible polymer in a solvent to form a polymer solution and also separately dispersing a metal cation component and a biologically active agent within said polymer solution. The polymer solution is then solidified to form a polymeric matrix, wherein at least a significant portion of the metal cation component is dispersed in the polymeric matrix separately from the biologically active protein, and whereby the metal cation component modulates the release of the biologically active agent from the polymeric matrix.
This invention has the advantage of modulating the release of a biologically active agent in vivo from a biodegradable polymer, thereby enhancing the control of the level of prophylactic, therapeutic and diagnostic agents released in vivo and lengthening the period during which controlled release can be maintained for a single dose.


REFERENCES:
patent: 3523906 (1970-08-01), Vrancken et al.
patent: 3691090 (1972-09-01), Kitajima et al.
patent: 3737337 (1973-06-01), Schnoring et al.
patent: 3887699 (1975-06-01), Yolles
patent: 3891570 (1975-06-01), Fukushima et al.
patent: 3928566 (1975-12-01), Briggs et al.
patent: 4166800 (1979-09-01), Fong
patent: 4235236 (1980-11-01), Theeuwes
patent: 4237114 (1980-12-01), Cardarelli
patent: 4252791 (1981-02-01), Grossberg et al.
patent: 4389330 (1983-06-01), Tice et al.
patent: 4391797 (1983-07-01), Folkman et al.
patent: 4530840 (1985-07-01), Tice et al.
patent: 4530901 (1985-07-01), Weissmann
patent: 4542025 (1985-09-01), Tice et al.
patent: 4637905 (1987-01-01), Gardner
patent: 4655777 (1987-04-01), Dunn et al.
patent: 4675189 (1987-06-01), Kent et al.
patent: 4711782 (1987-12-01), Okada et al.
patent: 4732889 (1988-03-01), Cynshi et al.
patent: 4767628 (1988-08-01), Hutchinson
patent: 4806524 (1989-02-01), Kawaguchi et al.
patent: 4835139 (1989-05-01), Tice et al.
patent: 4853218 (1989-08-01), Yim et al.
patent: 4871538 (1989-10-01), Yim et al.
patent: 4879272 (1989-11-01), Shimoda et al.
patent: 4891225 (1990-01-01), Langer et al.
patent: 4897268 (1990-01-01), Tice et al.
patent: 4906474 (1990-03-01), Langer et al.
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 4981696 (1991-01-01), Loomis et al.
patent: 4985404 (1991-01-01), Mitchell
patent: 4992419 (1991-02-01), Woog et al.
patent: 5019400 (1991-05-01), Gombotz et al.
patent: 5075115 (1991-12-01), Brine
patent: 5122367 (1992-06-01), Ron et al.
patent: 5126147 (1992-06-01), Silvestri et al.
patent: 5145674 (1992-09-01), Lane et al.
patent: 5176907 (1993-01-01), Leong
patent: 5192741 (1993-03-01), Orsolini et al.
patent: 5344654 (1994-09-01), Rueger et al.
patent: 5413797 (1995-05-01), Khan et al.
patent: 5441734 (1995-08-01), Reichert et al.
patent: 5656297 (1997-08-01), Bernstein et al.
patent: 5912015 (1999-06-01), Bernstein et al.
patent: 0 123 291 (1984-10-01), None
patent: 0 251 680 (1988-01-01), None
patent: 0266119 (1988-05-01), None
patent: 0 281 299 (1988-09-01), None
patent: 0 307 097 (1989-03-01), None
patent: 0330180 (1989-08-01), None
patent: 0537559 (1993-04-01), None
patent: 0580 428 (1994-01-01), None
patent: 0633 020 (1995-01-01), None
patent: 89/03678 (1989-05-01), None
patent: 90/09166 (1990-08-01), None
patent: 90/13285 (1990-11-01), None
patent: 90/13780 (1990-11-01), None
patent: 0 595 030 (1991-09-01), None
patent: 91/12882 (1991-09-01), None
patent: 91/18927 (1991-12-01), None
patent: 92/11844 (1992-07-01), None
patent: 92/19226 (1992-11-01), None
patent: 93/02712 (1993-02-01), None
patent: 93/07861 (1993-04-01), None
patent: 93/17668 (1993-09-01), None
patent: 93/25221 (1993-12-01), None
patent: 94/07469 (1994-04-01), None
patent: 94/12158 (1994-06-01), None
patent: 94/19373 (1994-09-01), None
patent: 95/11010 (1995-04-01), None
patent: 95/29664 (1995-11-01), None
patent: 96/07399 (1996-03-01), None
Pratt, L., et al., “The Effect of Ionic Electrolytes on Hydrolytic Degradation of Biodegradable Polymers: Mechanical and Thermodynamic Properties and Molecular Modeling,”J Polymer Science31(7) :1759-1769 (1993).
Costantino, H. R., et al., “Solid-Phase Aggregation of Proteins under Pharmaceutically Relevant Conditions,”J. of Pharmaceutical Sciences,83 (12) :1662-1669 (1994).
Costantino, H. R., et al., “Moisture-Induced Aggregation of Lyophilized Insulin,”Pharmaceutical Research,11(1) :21-29 (1994).
Costantino, H.R., et al., “Aggregation of a Lyophilized Pharmaceutical Protein, Recombinant Human Albumin: Effect of Moisture and Stabilization by Excipients,”Biotechnology,13 :493-496 (1995).
Creighton, T.E., “Physical Forces That Determine the Properties of Proteins,” In Proteins, Structures and Molecular Principles, (NY: W.H. Freeman and Company), pp. 149-150.
Cunningham, B. C., et al., “Dimerization of Human Growth Hormone by Zinc,”Science,253:545-548 (Aug. 1991).
Sato, Toyomi, et al., “Porous Biodegradable Microspheres for Controlled Drug Delivery. I. Assessment of Processing Conditions and Solvent Removal Techniques,”Pharmaceutical Research,5(1) :21-29 (1988).
Langer, R., “New Methods of Drug Delivery,”Science,249:1527-1533 (Sep. 1990).
Liu, W. R., et al., “Moisture-Induced Aggregation of Lyophilized Proteins in the Solid State,”Biotechnology and Bioengineering,37:177-184 (1991).
Lu, W., and Park, T. G., “Protein Release from Poly(lactic-co-glycolic acid) Microspheres: Protein Stability Problems,” PDA J. of Pharmaceutical Science & Technology, 49 (1) :13-19 (Jan-Feb 1995).
Cohen, S., et al., “Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres,”Pharmaceutical Research,8 (6) :713-720 (1991).
Hora, M.S. et al., “Release of Human Serum Albumin from Poly (lactide-co-glycolide) Microspheres,”Pharmaceutical Research,7 (11) :1190-1194 (1990).
Hageman, M.J., et al., “Preformulation Studies Oriented Toward Sustained Delivery of Recombinant Somatotropins,”J. Agric. Food Chem.,40:348-355 (1992).
Cleland, J. L., et al., “Characterization of Recombinant Human Growth Hormone-PLGA Formulations in Animals,”Proceed, Intern. Symp. Control. Rel. Bioact. Mater.,22:143-144 (1995).
Cleland, J. L., et al., “One Month Continuous Release Recombinant Human Growth Hormone-PLGA Formulations,”Proceed. Intern. Symp. Control. Rel

Affiliated with

Also associated with

Rating

Modulated release from biocompatible polymers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulated release from biocompatible polymers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulated release from biocompatible polymers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2823914